Sanofi’s myeloma antibody shines at ASCO, but where will it fit into treatment?
While isatuximab with Celgene's Pomalyst beat Pomalyst with steroid alone, the bigger question is how it will fare on the market versus J&J's Darzalex, which will likely soon be available as an easier-to-use subcutaneous injection.